Raven Biotechnologies, Inc.
Records under this name other than patents Raven Biotechnologies, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned.
Back to Raven Biotechnologies, Inc.
Confidence:Highevery input resolvedMediumone input unresolvedLowtwo or more caveatsUSPTO recordfrom USPTO's bulk records, without the patent's file history
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 7,527,969 | Novel RAAG10 Cell Surface Target and a Family of Antibodies Recognizing That Target Formerly held Term ended Term ended Oct 7, 2025 · High confidence | Term ended | Term ended Oct 7, 2025 | High confidence |
| US 8,779,098 | Novel B7-H3L Cell Surface Antigen and Antibodies That Bind Thereto Formerly held Term ended Term ended Aug 11, 2024 · High confidence | Term ended | Term ended Aug 11, 2024 | High confidence |
| US 9,574,007 | Novel B7-H3L Cell Surface Antigen and Antibodies That Bind Thereto Formerly held Term ended Term ended Sep 9, 2023 · High confidence | Term ended | Term ended Sep 9, 2023 | High confidence |
| US 7,718,774 | TES7 and antibodies that bind thereto Formerly held Lapsed on the fee record Ended May 18, 2022 · USPTO record | Lapsed on the fee record | Ended May 18, 2022 | USPTO record |
| US 7,674,619 | ADAM-9 modulators Formerly held Lapsed on the fee record Ended Mar 9, 2022 · USPTO record | Lapsed on the fee record | Ended Mar 9, 2022 | USPTO record |
| US 7,572,895 | Transferrin receptor antibodies Formerly held Lapsed on the fee record Ended Aug 11, 2021 · USPTO record | Lapsed on the fee record | Ended Aug 11, 2021 | USPTO record |
| US 7,569,672 | Antibodies that bind to EphA2 and methods of use thereof Formerly held Lapsed on the fee record Ended Aug 4, 2021 · USPTO record | Lapsed on the fee record | Ended Aug 4, 2021 | USPTO record |
| US 7,078,231 | Human pancreatic epithelial progenitor cells and methods of isolation and use thereof Formerly held Term ended Term ended Feb 5, 2021 · USPTO record | Term ended | Term ended Feb 5, 2021 | USPTO record |
| US 8,361,475 | ADAM-9 modulators Formerly held Lapsed on the fee record Ended Jan 29, 2021 · USPTO record | Lapsed on the fee record | Ended Jan 29, 2021 | USPTO record |
| US 8,309,354 | Human cancer stem cells Formerly held Lapsed on the fee record Ended Nov 13, 2020 · USPTO record | Lapsed on the fee record | Ended Nov 13, 2020 | USPTO record |